Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- MTPC, JCRS to Integrate Their Plasma Fraction Products Business in April 2012
July 4, 2011
- Actos Generics Launched Despite Various Issues
July 4, 2011
- FUJIFILM, Mitsubishi Corp. Tie-up to Contract Manufacture Biopharmaceuticals
July 4, 2011
- Nihon Chouzai to Invest ¥10 Bil. to Increase GE Production Capacity
July 4, 2011
- Price Settlement Rate Up to 93.9% in March: Korosho
July 4, 2011
- FDA Approves Generics of Levofloxacin from 12 Companies
July 4, 2011
- Equa Ranked No. 1 Both in GP, HP Markets in April: RepTrack Survey
July 4, 2011
- Industry Submits Proposal to Freeze Prices of Essential Drugs
July 4, 2011
- Korosho Designates 5 Products including Dornase as Orphan Drugs
July 4, 2011
- Ethical Drug Market in Japan Grew 1.6% to ¥9,035,806 Mil. in FY2010: IMS Japan
July 4, 2011
- METI Advisory Committee Proposes Exclusion of OTC-like Drugs from Insurance Coverage
July 4, 2011
- Sprycel Approved as 1st-line Treatment for CML: Bristol-Myers, Otsuka
July 4, 2011
- Wakamoto Licenses Ophthalmic Surgical Adjuvant from Kyushu Univ. Bioventure
July 4, 2011
- PMDA to Give Priority to Regenerative Medicine, Cancer in Regulatory Strategy Consultation
July 4, 2011
- Number of Deaths Reached Post-war High in 2010: Korosho
July 4, 2011
- Astellas Transfers Luvox to Abbott Japan
July 4, 2011
- Korosho Asks Takeda to Revise Package Insert for Actos
July 4, 2011
- With Right Infrastructure, “Bright Future”for Multinational Trials: Mr Morimoto of CMIC
July 4, 2011
- Sosei Group to Collaborate with Gifu Pharm. Univ.
July 4, 2011
- Korosho Instructs Revision of Package Inserts for Pioglitazone
July 4, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…